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Three recent trials (Resynchronization
reVErses Remodeling in Systolic Left vEntricular
Dysfunction [REVERSE], MADIT-CRT, and Re-
synchronization-Defibrillation for Ambulatory
Heart Failure [RAFT]) [1–3] have demonstrated the
benefit of cardiac resynchronization therapy (CRT)
in a relatively large number of New York Heart As-
sociation (NYHA) class II heart failure (HF) patients
with a wide QRS complex, and a much smaller
NYHA class I group of asymptomatic patients with
severe left ventricular (LV) dysfunction also with
a wide QRS complex. These trials generated a large
number of substudies, meta-analyses and review ar-
ticles about CRT in NYHA asymptomatic class I pa-
tients and class II  HF patients and fostered the ex-
pansion of indications for CRT. The large number
of publications about CRT has created or reactivat-
ed problems with the terminology of HF a situation
compounded by the common misinterpretation of
the NYHA classification [4]. The following descrip-
tions from recent publications illustrate how con-
fusing the terminology of HF has become. Descrip-
tions such as “severe”, “chronic” and “refractory”
used alone are excluded.
1. HF with mild symptoms. Also “…mildly
symptomatic patients with heart failure”. This ter-
minology is acceptable but the definition of mild
symptoms is missing. Presumably it refers to
functional class II NYHA, but not class I [4–6].
2. Mild HF. Does the word “mild” refer to the de-
gree of structural myocardial disease or symp-
toms? It probably refers to functional NYHA
class II rather than the severity of structural he-
art disease. HF as a diagnosis is never a “mild”
condition because of the seriousness of underly-
ing pathology and  poor prognosis [7–15].
3. Minimally symptomatic HF. What are mi-
nimal symptoms? What is difference between
“mild” and “minimal” symptoms? This descrip-
tion should not include asymptomatic NYHA
class I patients [16].
4. Minimal HF. Does the word “minimal” refer
to the underlying structural heart disease or
symptoms? It probably refers to functional
NYHA class II rather than the severity of struc-
tural heart disease but it should be clearly sta-
ted. HF is never minimal problem because the
seriousness of the underlying pathology and
the poor prognosis regardless of symptoms.
What is the difference between mild and mini-
mal symptoms? HF? [17].
5. Patients with less symptomatic HF. This
was part of a meta-analysis of CRT and focu-
sed on patients in NYHA class I and II [18].
6. Mild-to-moderate HF. The terms “mild” and
“moderate” are not defined. This terminology is
vague and probably refers to symptoms from
a functional class II and/or III NYHA rather than
the severity of structural heart disease [3, 19, 20].
7. Moderate HF. There is a difference between
HF with mild symptoms [4] and moderate HF
[21].  What is “moderate” HF? Class II and/or
III NYHA class?
8. Moderate-to-severe HF. The terms “modera-
te” and “severe” are not defined. This termino-
logy is vague and probably describes severe
symptoms rather than structural heart disease.
This terminology has been applied to functional
NYHA class III and/or IV patients. What is the
real difference between mild-to-moderate HF
and moderate-to-severe HF? Both overlap as
they both include “moderate” but how? [22–25].
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9. Advanced HF. This term is vague and may re-
fer to pathologic findings or symptoms presu-
mably in patients in functional class III or IV
NYHA [26–31].
10. Dyssynchronous HF. A dyssynchronopathy
status with HF can be induced in dogs with
experimental left bundle branch block [32–35].
As far as dyssynchronous HF is concerned,
a small proportion of CRT responders norma-
lize their LV ejection fraction [36]. Therefore
dyssynchronous HF is a diagnosis of exclusion
[35, 36] that can only be made after long-term
follow-up of patients with nonischemic cardio-
myopathy. The diagnosis can be confirmed by
turning off CRT whereupon LV function will
gradually deteriorate with the passage of time.
11. End-stage HF. This term is also imprecise
[37–40].
12. Terminal HF. “Terminal” is not defined. Ano-
ther imprecise term [41, 42].
13. Asymptomatic HF. This description appears
in the literature [43–45] and more recently on
the Internet (third party insurers, etc.) in rela-
tion to CRT [46–49]. This entity does not exist
because HF by definition must have congestion
and be symptomatic though the symptoms may
sometimes be unimpressive. This mistake is
similar to using “class I NYHA HF” to descri-
be HF incorrectly in an asymptomatic patient
with substantial LV dysfunction. Some articles
are written in a way that suggests the existen-
ce of asymptomatic HF. For example a poorly
worded title stating a mode of therapy “in
asymptomatic and mildly symptomatic heart
failure patients,” can be easily interpreted as
involving asymptomatic HF patients [5, 50–54].
In this respect Dhir [55] correctly called a si-
milar study “in mildly symptomatic heart failu-
re patients and asymptomatic patients” [56,
57]. It is also incorrect to state that a study
involved patients with “NYHA class I/II heart
failure.” This also suggests that both class I
and II patients have HF.
14. Changing HF functional NYHA class. In the
MADIT-CRT trial, 10% of patients started at
a higher NYHA class (III or IV) than the one as-
signed upon entry in the trial which enrolled
NYHA class I and II patients [2]. The REVERSE
trial included NYHA class I patients only if they
had moved from a higher class to class I at the
time of entry into the trial [2]. HF is a dynamic
process so the question arises as to whether one
should base therapeutic decisions on the histori-
cally worst NYHA class or the current class.
The problems with HF terminology are com-
pounded by the presence of multiple definitions of
HF circulating in the literature and the limitations
of the NYHA classification. The significance of the
HF definition problem and the need for a uniform
definition have been identified but little or no
progress has occurred [58–60]. The NYHA classi-
fication is subjective and there is little evidence for
its reliability or reproducibility. Substantial variabil-
ity exits in assigning a NYHA class [61–65]. The
time has come for the various learned cardiology
societies to standardize HF terminology and possi-
bly improve the NYHA functional classification.
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